General Information of Drug (ID: DMHZV7X)

Drug Name
Golimumab
Synonyms Simponi (TN); Golimumab (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Psoriatic arthritis FA21 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Ulcerative colitis DD71 Approved [3]
Inflammatory bowel disease DD72 Phase 2/3 [4]
Drug Type
Antibody
ADMET Property
Clearance
The sytemic clearance of drug is 4.9-6.7 mL/day/kg []
Half-life
The concentration or amount of drug in body reduced by one-half in 2 weeks [5]
Vd
The volume of distribution (Vd) of drug is 0.058-0.126 L/kg []
Cross-matching ID
DrugBank ID
DB06674
TTD ID
D09FSG
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Golimumab
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Golimumab and Upadacitinib. Rheumatoid arthritis [FA20] [7]
Coadministration of a Drug Treating the Disease Different from Golimumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Altered metabolism of Golimumab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [7]
Siltuximab DMGEATB Major Additive immunosuppressive effects by the combination of Golimumab and Siltuximab. Anemia [3A00-3A9Z] [8]
Dupilumab DMOAD2Y Major Additive immunosuppressive effects by the combination of Golimumab and Dupilumab. Atopic eczema [EA80] [8]
Eribulin DM1DX4Q Major Additive immunosuppressive effects by the combination of Golimumab and Eribulin. Breast cancer [2C60-2C6Y] [8]
Talazoparib DM1KS78 Major Additive immunosuppressive effects by the combination of Golimumab and Talazoparib. Breast cancer [2C60-2C6Y] [8]
LY2835219 DM93VBZ Major Additive immunosuppressive effects by the combination of Golimumab and LY2835219. Breast cancer [2C60-2C6Y] [8]
Pralatrexate DMAO80I Major Additive immunosuppressive effects by the combination of Golimumab and Pralatrexate. Breast cancer [2C60-2C6Y] [8]
Palbociclib DMD7L94 Major Additive immunosuppressive effects by the combination of Golimumab and Palbociclib. Breast cancer [2C60-2C6Y] [8]
Cabazitaxel DMPAZHC Major Additive immunosuppressive effects by the combination of Golimumab and Cabazitaxel. Breast cancer [2C60-2C6Y] [8]
Aflibercept DMT3D5I Major Additive immunosuppressive effects by the combination of Golimumab and Aflibercept. Colorectal cancer [2B91] [8]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Golimumab due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [7]
Polatuzumab vedotin DMF6Y0L Major Additive immunosuppressive effects by the combination of Golimumab and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [8]
Lisocabtagene maraleucel DMP45ME Major Additive immunosuppressive effects by the combination of Golimumab and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [8]
Axicabtagene ciloleucel DMYHN59 Major Additive immunosuppressive effects by the combination of Golimumab and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [8]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Golimumab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [9]
Bay 80-6946 DMLOS5R Major Additive immunosuppressive effects by the combination of Golimumab and Bay 80-6946. Follicular lymphoma [2A80] [8]
Avapritinib DMK2GZX Major Additive immunosuppressive effects by the combination of Golimumab and Avapritinib. Gastrointestinal stromal tumour [2B5B] [8]
177Lu-DOTATATE DMT8GVU Major Additive immunosuppressive effects by the combination of Golimumab and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [8]
Brentuximab vedotin DMWLC57 Major Additive immunosuppressive effects by the combination of Golimumab and Brentuximab vedotin. Hodgkin lymphoma [2B30] [8]
Levamlodipine DM92S6N Moderate Altered metabolism of Golimumab due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [7]
Brigatinib DM7W94S Major Additive immunosuppressive effects by the combination of Golimumab and Brigatinib. Lung cancer [2C25] [8]
Lurbinectedin DMEFRTZ Major Additive immunosuppressive effects by the combination of Golimumab and Lurbinectedin. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Major Additive immunosuppressive effects by the combination of Golimumab and Osimertinib. Lung cancer [2C25] [8]
Belimumab DM3OBQF Major Additive immunosuppressive effects by the combination of Golimumab and Belimumab. Lupus erythematosus [4A40] [8]
Obinutuzumab DM3BVAE Major Additive immunosuppressive effects by the combination of Golimumab and Obinutuzumab. Mature B-cell leukaemia [2A82] [8]
Idelalisib DM602WT Major Additive immunosuppressive effects by the combination of Golimumab and Idelalisib. Mature B-cell leukaemia [2A82] [8]
GDC-0199 DMH0QKA Major Additive immunosuppressive effects by the combination of Golimumab and GDC-0199. Mature B-cell leukaemia [2A82] [8]
IPI-145 DMWA24P Major Additive immunosuppressive effects by the combination of Golimumab and IPI-145. Mature B-cell leukaemia [2A82] [8]
Acalabrutinib DM7GCVW Major Additive immunosuppressive effects by the combination of Golimumab and Acalabrutinib. Mature B-cell lymphoma [2A85] [8]
Blinatumomab DMGECIJ Major Additive immunosuppressive effects by the combination of Golimumab and Blinatumomab. Mature B-cell lymphoma [2A85] [8]
Ibrutinib DMHZCPO Major Additive immunosuppressive effects by the combination of Golimumab and Ibrutinib. Mature B-cell lymphoma [2A85] [8]
Tisagenlecleucel DMM9BJD Major Additive immunosuppressive effects by the combination of Golimumab and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [8]
Ponatinib DMYGJQO Major Additive immunosuppressive effects by the combination of Golimumab and Ponatinib. Mature B-cell lymphoma [2A85] [8]
Carfilzomib DM48K0X Major Additive immunosuppressive effects by the combination of Golimumab and Carfilzomib. Multiple myeloma [2A83] [8]
Selinexor DMBD4K3 Major Additive immunosuppressive effects by the combination of Golimumab and Selinexor. Multiple myeloma [2A83] [8]
Belantamab mafodotin DMBT3AI Major Additive immunosuppressive effects by the combination of Golimumab and Belantamab mafodotin. Multiple myeloma [2A83] [8]
Daratumumab DMKCIUZ Major Additive immunosuppressive effects by the combination of Golimumab and Daratumumab. Multiple myeloma [2A83] [8]
Tecfidera DM2OVDT Major Additive immunosuppressive effects by the combination of Golimumab and Tecfidera. Multiple sclerosis [8A40] [8]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Golimumab and Siponimod. Multiple sclerosis [8A40] [10]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Golimumab and Fingolimod. Multiple sclerosis [8A40] [11]
Ocrelizumab DMEZ2KH Major Additive immunosuppressive effects by the combination of Golimumab and Ocrelizumab. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Golimumab and Ozanimod. Multiple sclerosis [8A40] [7]
Deflazacort DMV0RNS Major Additive immunosuppressive effects by the combination of Golimumab and Deflazacort. Muscular dystrophy [8C70] [8]
Ruxolitinib DM7Q98D Major Additive immunosuppressive effects by the combination of Golimumab and Ruxolitinib. Myeloproliferative neoplasm [2A20] [8]
Inebilizumab DMI0RHA Major Additive immunosuppressive effects by the combination of Golimumab and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [8]
Atezolizumab DMMF8U0 Major Additive immunosuppressive effects by the combination of Golimumab and Atezolizumab. Non-small cell lung cancer [2C25] [8]
Olaparib DM8QB1D Major Additive immunosuppressive effects by the combination of Golimumab and Olaparib. Ovarian cancer [2C73] [8]
Rucaparib DM9PVX8 Major Additive immunosuppressive effects by the combination of Golimumab and Rucaparib. Ovarian cancer [2C73] [8]
MK-4827 DMLYGH4 Major Additive immunosuppressive effects by the combination of Golimumab and MK-4827. Ovarian cancer [2C73] [8]
Brodalumab DMASDQ6 Major Additive immunosuppressive effects by the combination of Golimumab and Brodalumab. Psoriasis [EA90] [8]
Tildrakizumab DMLW9HG Major Additive immunosuppressive effects by the combination of Golimumab and Tildrakizumab. Psoriasis [EA90] [8]
Risankizumab DMM32GT Major Additive immunosuppressive effects by the combination of Golimumab and Risankizumab. Psoriasis [EA90] [8]
Ixekizumab DMXW92T Major Additive immunosuppressive effects by the combination of Golimumab and Ixekizumab. Psoriasis [EA90] [8]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Golimumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [12]
Mogamulizumab DMISH0Z Major Additive immunosuppressive effects by the combination of Golimumab and Mogamulizumab. Sezary syndrome [2B02] [8]
LEE011 DMMX75K Major Additive immunosuppressive effects by the combination of Golimumab and LEE011. Solid tumour/cancer [2A00-2F9Z] [8]
Pomalidomide DMTGBAX Major Additive immunosuppressive effects by the combination of Golimumab and Pomalidomide. Systemic sclerosis [4A42] [8]
Plicamycin DM7C8YV Major Additive immunosuppressive effects by the combination of Golimumab and Plicamycin. Testicular cancer [2C80] [8]
Belatacept DMXLYQF Major Additive immunosuppressive effects by the combination of Golimumab and Belatacept. Transplant rejection [NE84] [8]
Durvalumab DM4PVDY Major Additive immunosuppressive effects by the combination of Golimumab and Durvalumab. Ureteral cancer [2C92] [8]
⏷ Show the Full List of 60 DDI Information of This Drug

References

1 Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
2 ClinicalTrials.gov (NCT02390700) Observational Study of Golimumab Intravenous Infusion
3 Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6776).
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
9 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
10 Cerner Multum, Inc. "Australian Product Information.".
11 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
12 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]